Reuters logo
BRIEF-GSK's lung drug gains approval in Japan
December 2, 2016 / 7:15 AM / a year ago

BRIEF-GSK's lung drug gains approval in Japan

Dec 2 (Reuters) - GlaxoSmithKline Plc

* Relvar Ellipta approved in japan for COPD

* Relvar Ellipta 100/25 mcg gains approval in Japan for use in patients with COPD

* Japanese ministry of health, labour and welfare (MHLW) has approved Relvar Ellipta (Fluticasone Furoate / Vilanterol 100/25 mcg)

* Relvar Ellipta has been approved in Japan for treatment of asthma since 2013 in two strengths - 100/25 mcg and 200/25 mcg Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below